Pelthos Therapeutics (NYSEAMERICAN:PTHS) executives detailed the company’s path to the public markets, early commercial traction for its lead product ZELSUVMI, and plans to add two additional pediatri ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Pontiac placed first in just four events, but scored runnerup points nine times en route to tallying 146 points. Only New Lenox (Providence) fared better Tuesday evening at the 49 th annual Pontiac ...

Pelthos Therapeutics Inc (PTHS) reports a 129% increase in prescriptions and strategic acquisitions, bolstering its financial ...

Pelthos Therapeutics Inc. (NYSE:PTHS) on Thursday announced the launch of Zelsuvmi (berdazimer) topical gel 10.3% for molluscum contagiosum (molluscum) in adults and pediatric patients one year of age ...

According to TipRanks.com, Hendrix is a 4-star analyst with an average return of 5.6% and a 51.0% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Concentra Group ...

Pelthos Therapeutics Inc. (PTHS) stock price is 23.12 and Pelthos Therapeutics Inc. (PTHS) 10-day simple moving average is 23.69. Pelthos Therapeutics Inc. (PTHS) stock price is 23.12 and Pelthos ...

Good morning, everyone, and welcome to Pelthos Therapeutics 2025 Fourth Quarter and Fiscal Year Financial Results Conference Call. Pelthos issued a press release today announcing its financial results ...